GLP-1 RAs offer new opportunities to manage T2DM, while also adding additional value in reducing the burden of obesity and overweight, as well as preventing cardiovascular disease. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.